Holen Sie sich die Stockscreener-App
280.08
1.94%
-5.55
Schlusskurs vom Vortag:
$285.63
Offen:
$286.28
24-Stunden-Volumen:
328.87K
Relative Volume:
1.68
Marktkapitalisierung:
$7.84B
Einnahmen:
$2.58B
Nettoeinkommen (Verlust:
$-778.69M
KGV:
-10.25
EPS:
-27.33
Netto-Cashflow:
$223.75M
1W Leistung:
+1.05%
1M Leistung:
-20.85%
6M Leistung:
-11.43%
1J Leistung:
-17.29%
1-Tages-Spanne:
$275.97
$286.91
1-Wochen-Bereich:
$275.50
$289.96
52-Wochen-Spanne:
$262.12
$387.99
Bio Rad Laboratories Inc Stock (BIO) Company Profile
Firmenname
Bio Rad Laboratories Inc
Sektor
Branche
Telefon
(510) 724-7000
Adresse
1000 ALFRED NOBEL DRIVE, HERCULES
Vergleichen Sie BIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BIO
Bio Rad Laboratories Inc
|
280.08 | 7.84B | 2.58B | -778.69M | 223.75M | -27.33 |
|
ABT
Abbott Laboratories
|
134.92 | 234.01B | 41.95B | 13.40B | 6.49B | 7.65 |
|
BSX
Boston Scientific Corp
|
104.49 | 154.20B | 16.75B | 1.85B | 2.37B | 1.25 |
|
SYK
Stryker Corp
|
382.78 | 146.06B | 22.60B | 2.99B | 3.49B | 7.76 |
|
MDT
Medtronic Plc
|
89.94 | 115.42B | 33.20B | 4.26B | 5.47B | 3.29 |
|
EW
Edwards Lifesciences Corp
|
73.30 | 43.23B | 5.72B | 4.17B | 490.10M | 6.97 |
Bio Rad Laboratories Inc Stock (BIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-10-01 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-08-28 | Eingeleitet | Wells Fargo | Equal Weight |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-04-03 | Herabstufung | Citigroup | Buy → Neutral |
| 2023-12-07 | Eingeleitet | UBS | Buy |
| 2023-06-16 | Eingeleitet | Wells Fargo | Overweight |
| 2022-12-07 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-01-28 | Bestätigt | Citigroup | Buy |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Buy |
| 2018-10-17 | Eingeleitet | Goldman | Buy |
| 2018-09-20 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2018-02-16 | Herabstufung | CL King | Buy → Neutral |
| 2017-07-13 | Eingeleitet | Wells Fargo | Outperform |
| 2017-06-28 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2017-01-18 | Eingeleitet | Deutsche Bank | Hold |
| 2016-10-13 | Eingeleitet | CL King | Buy |
| 2015-05-06 | Bestätigt | Jefferies | Buy |
| 2009-12-18 | Eingeleitet | Maxim Group | Buy |
| 2009-11-06 | Eingeleitet | Jefferies & Co | Buy |
| 2009-07-17 | Eingeleitet | Soleil | Buy |
| 2007-09-26 | Eingeleitet | Banc of America Sec | Buy |
| 2007-02-23 | Herabstufung | Robert W. Baird | Outperform → Neutral |
Alle ansehen
Bio Rad Laboratories Inc Aktie (BIO) Neueste Nachrichten
Bay Area biotech giant Bio-Rad to lay off hundreds after $1.8 billion loss - MSN
Bio-Rad Laboratories Updates on Sartorius Investment - TipRanks
Biosensors Market Generated Opportunities, Future Scope - openPR
Lateral Flow Immunoassay (LFIA) Based Rapid Test Market Report 2025: Key Trends, Major Players, Opportunities, Strategies, M&As, 2018-2023, 2028F, 2033F - GlobeNewswire Inc.
Strategic Financial Concepts LLC Buys New Shares in Bio-Rad Laboratories, Inc. (NYSE:BIO) - MarketBeat
Principal Securities Inc. Raises Stock Position in Bio-Rad Laboratories, Inc. (NYSE:BIO) - MarketBeat
Bio-Rad Laboratories (NYSE:BIO) Stock Rating Lowered by StockNews.com - MarketBeat
Global Rapid Microbiology Testing Market to Reach $10.62 - openPR
Empowered Funds LLC Makes New $443,000 Investment in Bio-Rad Laboratories, Inc. (NYSE:BIO) - MarketBeat
BIO Stock Might Rise Following the Offer to Acquire Stilla - MSN
Bio-Rad Laboratories, Inc. (NYSE:BIO) Q4 2024 Earnings Call Transcript - MSN
Bio-Rad sued by Caltech over DNA analysis technology - Reuters
Surface Plasmon Resonance Market Future Business - openPR
Bio-Rad's M&A ambitions continue with Stilla buyout - BioProcess Insider
Is There An Opportunity With Bio-Rad Laboratories, Inc.'s (NYSE:BIO) 39% Undervaluation? - Simply Wall St
Bio-Rad Laboratories (NYSE:BIO) Sees Large Volume Increase After Better-Than-Expected Earnings - MarketBeat
Bio-Rad Laboratories (NYSE:BIO) Issues Quarterly Earnings Results, Beats Estimates By $0.04 EPS - MarketBeat
Allspring Global Investments Holdings LLC Decreases Stock Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) - MarketBeat
Bio-Rad Laboratories (NYSE:BIO.B) Releases Quarterly Earnings Results - MarketBeat
Next Generation Sequencing NGS Market is Projected to Achieve - openPR
DNA Extraction Kits Market Poised for Significant Growth | Key - openPR
Van ECK Associates Corp Has $237.67 Million Stock Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) - MarketBeat
Bio-Rad set to acquire Stilla Technologies - MSN
Immuno-Oncology Assays Market Projected To Witness Substantial Growth, 2025-2032:Sartorius AG, Bio-Rad - EIN News
Chromatography Data System Market to Experience Booming Growth - openPR
Bio-Rad targets 1.5%-3.5% revenue growth in 2025 amid operational improvements and new acquisitions - MSN
Sumitomo Mitsui Trust Group Inc. Has $11.96 Million Stock Position in Bio-Rad Laboratories, Inc. (NYSE:BIO) - MarketBeat
Genomics Market Future Business Opportunities 2025-2032 | - openPR
Wells Fargo & Company Has Lowered Expectations for Bio-Rad Laboratories (NYSE:BIO) Stock Price - MarketBeat
Bio-Rad Laboratories (NYSE:BIO.B) Shares Gap DownWhat's Next? - MarketBeat
Bio-Rad price target lowered to $447 from $477 at RBC Capital - Yahoo Finance
Bio-Rad Labs stock down 4% as Q4 revenue and guidance miss expectations - MSN
Bio-Rad Laboratories (NYSE:BIO) Shares Down 4.2%Here's Why - MarketBeat
Oncocyte secures $29.1 million to advance FDA assay - MSN
Bio-Rad Laboratories (BIO) Misses Q4 Earnings and Revenue Estimates - MSN
BIO-RAD LABORATORIES, INC. SEC 10-K Report - TradingView
Earnings call transcript: Bio-Rad Q4 2024 results miss forecasts - MSN
Bay Area biotech giant to lay off hundreds after $1.8 billion loss - SFGATE
BIO Q4 Earnings and Revenues Miss Estimates, Stock Down Aftermarket - Yahoo Finance
Bio-Rad Earnings: In-Line Results, Guidance Slightly Below Expectations, Shares Undervalued - Morningstar
Bio-Rad's Expanding Profit Margins and Stake in Sartorius Drive Long-Term Value - Morningstar
Entropy Technologies LP Reduces Holdings in Bio-Rad Laboratories, Inc. (NYSE:BIO) - MarketBeat
Earnings call transcript: Bio-Rad Q4 2024 results miss forecasts By Investing.com - Investing.com Nigeria
Enzyme Linked Immunosorbent Assay Market Growth, Share, - openPR
Bio-Rad Laboratories Inc (BIO) Q4 2024 Earnings Call Highlights: Navigating Challenges with ... - Yahoo Finance
Bio-Rad Laboratories Inc (BIO) Q4 2024 Earnings Call Highlights: Navigating Challenges with ... By GuruFocus - Investing.com Canada
Finanzdaten der Bio Rad Laboratories Inc-Aktie (BIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.16%
0.10%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):